AMETOP GEL 4%

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

TETRACAINE (TETRACAINE HYDROCHLORIDE)

から入手可能:

VALEO PHARMA INC

ATCコード:

D04AB06

INN（国際名）:

TETRACAINE

投薬量:

40MG

医薬品形態:

GEL

構図:

TETRACAINE (TETRACAINE HYDROCHLORIDE) 40MG

投与経路:

TOPICAL

パッケージ内のユニット:

1.5G

処方タイプ:

Ethical

治療領域:

ANTIPRURITICS AND LOCAL ANESTHETICS

製品概要:

Active ingredient group (AIG) number: 0108851002; AHFS:

認証ステータス:

APPROVED

承認日:

2020-07-09

製品の特徴

_Product Monograph _
_ _
_AMETOP GEL 4% (_Tetracaine Hydrochloride Gel)_ _
_Page 1 of 14 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
AMETOP® GEL 4%
Tetracaine (as tetracaine hydrochloride)
Gel, Tetracaine 4% w/w, for topical administration
Topical Analgesic
Valeo Pharma Inc.
16667 Hymus Blvd.
Kirkland (Québec)
Canada H9H 4R9
Date of Initial Authorization:
JAN 17, 1997
Date of Revision:
April 5, 2022
Submission Control Number: 257974
AMETOP is a registered trademark of Alliance Pharmaceuticals Limited
© Alliance Pharmaceuticals Limited 2022
_Product Monograph _
_ _
_AMETOP GEL 4% (_Tetracaine Hydrochloride Gel)_ _
_Page 2 of 14 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
04/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................
2
TABLE OF CONTENTS
............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................................... 4
1
INDICATIONS
.............................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics
..................................................................................................................
4
2
CONTRAINDICATIONS
................................................................................................
4
4
DOSAGE AND ADMINISTRATION
................................................................................
4
4.2
Recommended Dose and Dosage Adjustment
........................................................ 4
4.4
Administration
.........................................................................................................
5
5
OVERDOS